ArticleOncoimmunology2020

A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.

Neeta Somaiah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.